• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Advance Lithium Corp
Amerant Bancorp Inc
Atlanticus Holdings Corporation - Common Stock
Bally's Corporation Common Stock
BlackRock Municipal Income Fund, Inc. Common Stock
Capstone Mining Corp
Champion Real Estate Investment Trust
Commercial National Financial Corp [Pa]
Container Store (The) Common Stock
D/B/A Compass Diversified Holdings Shares of Beneficial Interest
Endeavour Mng Plc
Everspin Technologies, Inc. - Common Stock
FRP Holdings, Inc. - Common Stock
GraniteShares 2x Long TDC Daily ETF
LuxUrban Hotels Inc. - Common Stock
Oregon Pacific Bncrp
Osprey Bitcoin Trust
Sonder Holdings Inc. - Class A Common Stock
Star Navigation Systems Group Ltd
University Bancorp Inc
Utah Medical Products, Inc. - Common Stock
Voya Global Advantage and Premium Opportunity Fund Common Shares of Beneficial
iRobot Corporation - Common Stock
Edit Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gain Therapeutics, Inc. - Common Stock (NQ:GANX)

1.290 +0.100 (+8.40%)
Delayed Quote Updated: 4:00 PM EDT, Oct 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,751,163
Open 1.180
Bid (Size) 1.320 (100)
Ask (Size) 1.340 (200)
Prev. Close 1.190
Today's Range 1.160 - 1.330
52wk Range 1.150 - 4.340
Shares Outstanding 27,132,588
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Gain Therapeutics to Attend the 2026 Maxim Growth Summit
October 08, 2026
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration
October 01, 2026
From Gain Therapeutics, Inc.
Via GlobeNewswire

Performance

52-Week Range 70.3% below 52-week high
1.290
1.1552W Low 4.3452W High
1 Week 6.3% below 1-week high
1.151W Low 1.381W High

Gain Therapeutics, Inc. - Common Stock (GANX) traded between $1.15 and $4.34 over the past 52 weeks and last traded at $1.29, 70.3% below its 52-week high. Over the past week it ranged between $1.15 and $1.38.

Past 12 Months
+2.4%
-33.8%
-29.1%
-31.7%
-59.4%
-35.8%
1W +$0.03
1M -$0.66
3M -$0.53
6M -$0.60
YTD -$1.89
1Y -$0.72

GANX was -35.8% over the past year, -31.7% over six months, -59.4% year to date, +2.4% in the last week.

12 Months vs Market
GANX
-35.8%
DIA
+13.3%
SPY
+14.4%
QQQ
+16.3%
IWM
+13.7%

Over the past 12 months GANX returned -35.8% versus DIA (Dow) +13.3%, SPY (S&P 500) +14.4%, QQQ (Nasdaq 100) +16.3% and IWM (Russell 2000) +13.7%.

Volume & Liquidity 5.51× 3-mo avg
Today 2,751,163 3-mo avg 499.6K
1W
975.2K
1M
638.9K
3M
499.6K
6M
682.5K
YTD
725.7K
1Y
880.3K

GANX most recently traded 2,751,163 shares against a 3-month average daily volume of 499.6K.

More News

Read More
News headline image
Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders
September 29, 2026
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference
September 17, 2026
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference
August 25, 2026
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update
August 11, 2026
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update
July 16, 2026
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
June 29, 2026
Via Benzinga
Wondering what's happening in today's after-hours session? ↗
June 29, 2026
Via Chartmill
News headline image
Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease
June 29, 2026
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
June 10, 2026
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026
May 26, 2026
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update
May 11, 2026
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026
April 24, 2026
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update
March 26, 2026
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics to Present at the 38th Annual ROTH Conference
March 19, 2026
From Gain Therapeutics, Inc.
Via GlobeNewswire
Which stocks are moving on Wednesday? ↗
March 18, 2026
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
March 18, 2026
Via Chartmill
News headline image
Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026
March 18, 2026
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update
March 12, 2026
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 19, 2026
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week
January 07, 2026
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287
January 06, 2026
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease
December 18, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Keep an eye on the top gainers and losers in Thursday's session. ↗
December 18, 2025
Via Chartmill

Frequently Asked Questions

Is Gain Therapeutics, Inc. - Common Stock publicly traded?
Yes, Gain Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Gain Therapeutics, Inc. - Common Stock trade on?
Gain Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Gain Therapeutics, Inc. - Common Stock?
The ticker symbol for Gain Therapeutics, Inc. - Common Stock is GANX on the Nasdaq Stock Market
What is the current price of Gain Therapeutics, Inc. - Common Stock?
The current price of Gain Therapeutics, Inc. - Common Stock is 1.290
When was Gain Therapeutics, Inc. - Common Stock last traded?
The last trade of Gain Therapeutics, Inc. - Common Stock was at 10/22/26 04:00 PM ET
What is the market capitalization of Gain Therapeutics, Inc. - Common Stock?
The market capitalization of Gain Therapeutics, Inc. - Common Stock is 35.00M
How many shares of Gain Therapeutics, Inc. - Common Stock are outstanding?
Gain Therapeutics, Inc. - Common Stock has 35M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap